[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"heart-failure-with-normal-ejection-fraction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:heart-failure-with-normal-ejection-fraction":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,70,103],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":26,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100345275","exercise-intolerance-in-heart-failure-100345275",false,"NCT03775577","Exercise Intolerance in Heart Failure","Exercise Intolerance in Heart Failure: the Role of Altered Cardiac and Skeletal Muscle Energetics","Inclusion Criteria:\n\n* Patients of either gender who are greater than 21 years of age (no upper age limit),\n* Permission of patient's clinical attending physician,\n* Previous clinical diagnosis of HF with current New York Heart Association (NYHA) Class II-III symptoms for at least 1 month,\n* Left ventricular ejection fraction (EF) \\>50% by echocardiography, MRI, CT or x-ray or nuclear ventriculography within prior 12 months,\n* Stable medical therapy for at least 30 days (no addition or removal or major (\\>100%) dose change of Renin-Angiotensin-Aldosterone System (RAAS) antagonists, beta-blockers, or calcium channel blockers for hypertension).\n\nExclusion Criteria:\n\n* Unable to understand the risks, benefits, and alternatives of participation and give meaningful consent,\n* Contraindications to MRI such as implanted metallic objects (pre-existing cardiac pacemakers, cerebral clips) or indwelling metallic projectiles,\n* Significant valvular abnormalities,\n* Pregnant women (women of childbearing potential will undergo blood or urine pregnancy testing),\n* History of clinical CAD or significant epicardial coronary disease (\\>50% stenosis) in major coronary artery by x-ray or CT angiography unless (a) the patient underwent prior successful revascularization with percutaneous coronary angioplasty within the prior three years and (b) there are no residual lesions of \\>50% on the most recent coronary angiographic study.\n* History of infiltrative cardiomyopathy or constrictive pericarditis,\n* Cor pulmonale,\n* Significant pulmonary disease,\n* Estimated glomerular filtration rate (eGFR) \\\u003C20ml\u002Fmin,\n* Any condition other than HF which could limit the ability to perform a 6MW or cardiopulmonary exercise test (CPET) test (e.g., critical peripheral vascular disease, significant orthopedic or neurological conditions),\n* Any diseases other than HF which are likely to significantly alter the patient's global perception of status or quality of life over a period of 6 months.\n* Significant peripheral vascular disease",true,"ALL","21 Years",{"count":20,"type":21},130,"ESTIMATED","OBSERVATIONAL","The investigators are studying whether metabolic abnormalities in cardiac and skeletal muscle in patients with heart failure with preserved ejection fraction (HFpEF) are associated with debilitating exercise intolerance.",[25],"Heart Failure With Normal Ejection Fraction",[27,28],"Heart Failure with Preserved Ejection Fraction","HFpEF","RECRUITING","2026-03-06",{"date":32,"type":33},"2026-03-09","ACTUAL",{"date":35,"type":33},"2017-04-01",{"date":37,"type":21},"2027-08",{"name":39,"class":40},"Johns Hopkins University","OTHER",1,{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":4,"eligibilityCriteria":48,"healthyVolunteers":16,"sex":17,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":4,"studyType":53,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":41},"100327931","imaging-histone-deacetylase-in-the-heart-100327931","NCT03549559","Imaging Histone Deacetylase in the Heart","Imaging of Histone Deacetylase in the Heart","Inclusion Criteria:\n\nGroup 1: Healthy Volunteers (n = 30)\n\n* Healthy adults with no known history of medical disease\n* Age 18-85 years\n* No history cardiovascular disease\n* Ability to provide informed consent\n\nGroup 2: Patients with Diabetes (n = 16)\n\n* Age 18-85 years\n* Diagnosis of diabetes\n* Echocardiogram within last 12 months showing no evidence of left ventricular hypertrophy or hemodynamic findings consistent with heart failure with preserved ejection fraction\n* Ability to provide informed consent\n\nGroup 3: Patients with Aortic Stenosis (n = 50)\n\n* Age 18-85 years\n* Echocardiogram or cardiac MRI scan within last 12 months documenting left ventricular hypertrophy and degenerative calcific aortic stenosis\n* Ability to provide informed consent\n\nExclusion Criteria:\n\n* Known contraindication to MRI","18 Years","85 Years",{"count":52,"type":21},96,"INTERVENTIONAL",[55],"NA","The overall goal of this PET-MR imaging trial is to evaluate 11C-Martinostat, a histone deacetylase targeted radioligand, in patients with aortic stenosis, individuals with diabetes, and healthy volunteers.",[25,58,59,60],"Left Ventricular Hypertrophy","Aortic Valve Stenosis","Diabetes","2025-12-18",{"date":63,"type":33},"2025-12-22",{"date":65,"type":33},"2018-09-07",{"date":67,"type":21},"2026-09-01",{"name":69,"class":40},"Massachusetts General Hospital",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":76,"eligibilityCriteria":77,"healthyVolunteers":16,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":78,"targetDuration":80,"studyType":22,"phases":4,"briefSummary":81,"conditions":82,"keywords":87,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":41},"100322647","biomechanical-precision-medicine-registry-for-patients-with-and-without-heart-failure-100322647","NCT03480633","Biomechanical Precision Medicine Registry for Patients With and Without Heart Failure","Preserved vs. Reduced Ejection Fraction Biomarker Registry and Precision Medicine Database for Ambulatory Heart Failure Patients (PREFER-HF) Study","PREFER-HF","Inclusion criteria for patients with HF:\n\n* 18 years and older\n* History of clinical symptoms consistent with HF and at least one of the following supporting evidence of HF:\n\n  * NT-proBNP \\> 125 pg\u002FmL\n  * BNP \\> 35 pg\u002FmL\n  * Capillary wedge pressure ≥ 15 mmHg on right heart catheterization or CI \\\u003C2.8 L\u002Fmin\u002Fm2\n  * LVEDP ≥ 15 mmHg\n  * Radiographic evidence of pulmonary edema\n  * Improvement in symptoms with diuretic initiation of increase\n  * CPET evidence of cardiac etiology of symptoms\n\nHFpEF: LVEF ≥ 50% HFrEF: LVEF \\\u003C50%\n\nExclusion criteria (for all patients, including both those with HFpEF and HFrEF):\n\n\\- End stage renal disease on dialysis",{"count":79,"type":21},3000,"50 Months","In this single-center, longitudinal observational study, we will comprehensively examine clinical characteristics, proteomic, metabolomic, genomic and imaging data to better understand how different heart failure types may develop and progress over time. We will evaluate distinct sub-groups of heart failure (also known as heart failure phenotypes) and cardiomyopathies including amyloidosis with an ultimate goal of bringing the right medications and therapy to the right patients to optimize benefit and minimized side effects, an effort to improve precision medicine in heart failure.",[25,83,84,85,86],"Heart Failure With Reduced Ejection Fraction","Heart Failure, Right Sided","Heart Failure With Mid Range Ejection Fraction","Cardiovascular Risk Factor",[88,89,90,91,92,93,94],"Heart failure","Precision medicine","High risk patients","Pathophysiology","Bioregistry","Biomarkers","Heart failure etiology","2025-12-02",{"date":97,"type":33},"2025-12-09",{"date":99,"type":33},"2016-04-07",{"date":101,"type":21},"2027-10-06",{"name":69,"class":40},{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":16,"sex":17,"minAge":49,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":41},"100306469","new-orleans-pulmonary-hypertension-biobank-100306469","NCT03269630","New Orleans Pulmonary Hypertension Biobank","NO-PH Biobank","Inclusion Criteria:\n\n* Diagnosis of pulmonary hypertension and followed at the Comprehensive Pulmonary Hypertension Center OR\n* Diagnosis of systemic sclerosis and followed at the Comprehensive Pulmonary Hypertension Center OR\n* Diagnosis of mixed connective tissue disease and followed at the Comprehensive Pulmonary Hypertension Center OR\n* Undergoing outpatient right heart catheterization\n\nExclusion Criteria:\n\n* Age\\\u003C18\n* Pregnant\n* Unable to understand English\n* Currently incarcerated\n* Unwilling or unable to sign informed consent",{"count":111,"type":21},450,"Pulmonary hypertension (PH) is a serious condition characterized by a mean pulmonary artery pressure \\>=25mmHg on right heart catheterization (RHC). Despite advances in PH care, outcomes are still sub-optimal and further research is required into the pathobiology of the disease and development of biomarkers that can guide clinical care. The investigators are establishing a biobank to collect samples (blood, urine, stool) from patients with pulmonary hypertension, patients at high risk for pulmonary hypertension, healthy controls, and patients undergoing right heart catheterization. Specimens will be stored for future investigations.",[114,115,116,25,117],"Pulmonary Hypertension","Systemic Sclerosis","Mixed Connective Tissue Disease","Healthy","2021-09-09",{"date":120,"type":33},"2021-09-10",{"date":122,"type":33},"2017-12-29",{"date":124,"type":21},"2027-10",{"name":126,"class":40},"Louisiana State University Health Sciences Center in New Orleans"]